ObjectiveThis study aims to investigate the expression of C20 in oral potentially malignant disorders (OPMDs) by using the histological analysis and evaluates the clinical value of using CD20 as indices to assess the carcinogenic potential of OPMDs.MethodsClinical data from 17 cases with oral hyperplasia mucosa, 21 cases with oral lichen planus (OLP), 15 cases with mild oral dysplasia mucosa (D1), and 9 cases with mild moderate dysplasia mucosa (D2) were analyzed by using retrospective analysis. Immunohistochemical analysis was applied to investigate the expression of CD20 in paraffin sections of oral hyperplasia mucosa, OLP, D1, and D2 tissues. Subsequently, the relationships between such expression and clinical factors were investigated.ResultsResults The positive rates of CD20 expression in the oral hyperplasia mucosa, OLP, D1, and D2 mucosa were 11.76%, 61.90%, 20.00%, and 66.67% (P<0 .05), respectively. cd20 expression was found uncorrelated with age, gender, region, alcohol use, and smoking status (P>0.05). The multiple-factor analysis showed that the odds ratios of OLP and D2 significantly increased (P<0 .05) when oral hyperplasia mucosa was used as the reference group.ConclusionCD20 may be used individually as clinical index to evaluate the carcinogenic potential of OPMDs.
